BR112018010489A8 - tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos - Google Patents

tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos

Info

Publication number
BR112018010489A8
BR112018010489A8 BR112018010489A BR112018010489A BR112018010489A8 BR 112018010489 A8 BR112018010489 A8 BR 112018010489A8 BR 112018010489 A BR112018010489 A BR 112018010489A BR 112018010489 A BR112018010489 A BR 112018010489A BR 112018010489 A8 BR112018010489 A8 BR 112018010489A8
Authority
BR
Brazil
Prior art keywords
softgel
capsule
tablet
tincture
humans
Prior art date
Application number
BR112018010489A
Other languages
English (en)
Other versions
BR112018010489A2 (pt
Inventor
J Carberry James
Original Assignee
Undoo Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58719928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018010489(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Undoo Llc filed Critical Undoo Llc
Publication of BR112018010489A2 publication Critical patent/BR112018010489A2/pt
Publication of BR112018010489A8 publication Critical patent/BR112018010489A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos as realizações da presente invenção se referem ao uso de uma quantidade terapeuticamente eficaz de olivetol para reduzir, eliminar, inibir ou aliviar os efeitos psicoativos de thc em usuários de cannabis. as realizações adicionais da presente invenção se referem a um softgel, comprimido ou cápsula de olivetol em combinação com um óleo comestível.
BR112018010489A 2015-11-23 2016-11-23 tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos BR112018010489A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258979P 2015-11-23 2015-11-23
PCT/US2016/063645 WO2017091755A1 (en) 2015-11-23 2016-11-23 Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body

Publications (2)

Publication Number Publication Date
BR112018010489A2 BR112018010489A2 (pt) 2018-11-13
BR112018010489A8 true BR112018010489A8 (pt) 2019-02-26

Family

ID=58719928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010489A BR112018010489A8 (pt) 2015-11-23 2016-11-23 tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos

Country Status (7)

Country Link
US (2) US9918947B2 (pt)
EP (1) EP3380092B1 (pt)
AU (1) AU2016361585A1 (pt)
BR (1) BR112018010489A8 (pt)
CA (1) CA3005047C (pt)
WO (1) WO2017091755A1 (pt)
ZA (1) ZA201804198B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048185B1 (fr) * 2016-02-25 2018-03-23 Parrot Drones Drone avec bras de liaison pliable.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1649671A (en) * 1926-11-05 1927-11-15 Sharp & Dohme Inc Hexyl resorcinol composition
US3734930A (en) * 1971-09-22 1973-05-22 R Razdan Direct synthesis of ({31 )-trans-{66 {11 tetrahydrocannabinol from olivetol and ({30 )-trans-{66 {11 -carene oxide
WO1995005156A1 (en) * 1993-08-17 1995-02-23 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
ES2150373B1 (es) 1998-07-21 2001-11-16 Biocosmetics Sl Capsulas de gelatina blanda que contienen aceite de oliva.
US20050152968A1 (en) * 2004-01-09 2005-07-14 Brophy Kristine M. Microemulsions for pharmaceutical compositions
WO2006017892A1 (en) 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
FR2893628B1 (fr) 2005-11-18 2008-05-16 Expanscience Laboratoires Sa Procede d'obtention d'une huile d'avocat raffinee riche en triglycerides et huile susceptible d'etre obtenue par un tel procede
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
WO2008139263A2 (en) 2006-11-30 2008-11-20 University Of Plymouth Methods for slowing the progression of multiple sclerosis
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
DE102012105063C5 (de) 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen

Also Published As

Publication number Publication date
WO2017091755A1 (en) 2017-06-01
CA3005047A1 (en) 2017-06-01
BR112018010489A2 (pt) 2018-11-13
US20170143643A1 (en) 2017-05-25
ZA201804198B (en) 2019-04-24
CA3005047C (en) 2023-10-17
EP3380092A1 (en) 2018-10-03
EP3380092B1 (en) 2021-12-29
AU2016361585A1 (en) 2018-07-12
US20170143644A1 (en) 2017-05-25
US9918947B2 (en) 2018-03-20
EP3380092A4 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
NZ726746A (en) Stable cannabinoid formulations
BR112019001794A2 (pt) composição de cannabis
PH12017502375A1 (en) Method of treating inflammation using natural compounds and/or diet
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
BR112017026241A2 (pt) composições farmacêuticas e alimentícias para induzir a saciação e prolongar a saciedade em indivíduos que necessitem das mesmas
MX2013003635A (es) Compuestos de n-heteroarilo.
BR112017020307A2 (pt) método para inibir os sintomas associados com a ingestão de álcool, e, composição farmacêutica
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
CL2018003502A1 (es) Métodos para tratar la osificación heterotópica.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]